Filing Details

Accession Number:
0001179022-18-000046
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-06 16:31:06
Reporting Period:
2018-06-04
Accepted Time:
2018-06-06 16:31:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557082 H. Harold Shlevin C/O Galectin Therapeutics, Inc.
4960 Peachtree Industrial Blvd., Ste 240
Norcross GA 30071
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-04 5,500 $2.32 59,414 No 4 M Direct
Common Stock Acquisiton 2018-06-04 5,407 $0.87 64,821 No 4 M Direct
Common Stock Disposition 2018-06-04 10,907 $5.15 53,914 No 4 S Direct
Common Stock Acquisiton 2018-06-05 5,630 $2.32 65,044 No 4 M Direct
Common Stock Acquisiton 2018-06-05 4,294 $0.87 69,338 No 4 M Direct
Common Stock Disposition 2018-06-05 9,924 $5.16 53,914 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2018-06-04 5,500 $0.00 5,500 $2.32
Common Stock Stock option (right to buy) Disposition 2018-06-04 5,407 $0.00 5,407 $0.87
Common Stock Stock option (right to buy) Disposition 2018-06-05 5,630 $0.00 5,630 $2.32
Common Stock Stock option (right to buy) Disposition 2018-06-05 4,294 $0.00 4,294 $0.87
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
85,000 2022-08-27 No 4 M Direct
84,893 2026-12-03 No 4 M Direct
79,370 2022-08-27 No 4 M Direct
80,599 2026-12-03 No 4 M Direct
Footnotes
  1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2018.
  2. The options vest as follows: 20% on August 27, 2012, the grant date; 20% on December 31, 2012; 30% on December 31, 2013; and 30% on December 31, 2014.
  3. The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017.
  4. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.16. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  5. The shares were sold in multiple transactions at prices ranging from $5.15 to $5.18. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.